VJHemOnc Podcast

Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets

The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions. 

In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, and Benjamin Derman, MD, University of Chicago, Chicago, IL, discuss several interesting topics in myeloma, including the challenges associated with sequencing anti-BCMA therapies, the prognostic value of circulating tumor cells (CTCs), and the growing role of quadruplet therapies in myeloma, with updates in this space from the 2023 ASH Annual Meeting.

Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy

In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated.

In this podcast, leading experts Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, and Josu de la Fuente, PhD, FRCP, FRCPI, FRCPCH, FRCPath, Imperial College London, London, UK, discuss key updates in SCD presented at the 2023 ASH Annual Meeting and Exposition. The experts cover several topics, including the pathogenesis of SCD, novel agents being explored, and the growing role of gene therapies.

ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis

In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients. 

In this podcast, you will hear from experts Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London Hospitals NHS Foundation Trust, London, UK, and Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, who discuss the latest updates in the treatment and management of AL amyloidosis at the 65th ASH Annual Meeting and Exposition.

MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF

The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made.

At the 65th ASH Annual Meeting and Exposition, leading experts Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shared their key highlights in MPNs, commenting on ongoing trials and promising combinations being explored, as well as future outlooks.

iwNHL 2023 Session V: Expanding the CAR platform in NHL

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, and David Miklos, MD, PhD, Stanford University, Stanford, CA, discuss the growing role of CAR-T therapy in NHL and further comment on how to expand the CAR platform in this disease setting.

iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials

The biennial International Workshop on Chronic Lymphocytic Leukemia^TM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL.

Tune in as we share some key highlights from this year's meeting. In this podcast, a variety of topics are covered, including the role of continuous BTK inhibitors (BTKis) in CLL, the importance of investigating the biology of Richter's transformation (RT), and the need to address the underrepresentation of elderly patients in CLL clinical trials. You will hear from several leading experts, including Kerry Rogers, MD, Ohio State University, Columbus, OH, Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd, CLL Society, Inc., Chula Vista, CA, Raul Cordoba, MD, PhD, University Hospital Fundación Jiménez Díaz, Madrid, Spain, and Adam Kittai, MD, Ohio State University, Columbus, OH.

iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Tanya Siddiqi, MD, City of Hope, Duarte, CA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discuss the role of BTK inhibitors and degraders in NHL. Following this, you will hear from Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who discuss the growing role of bispecific antibodies, including glofitamab, epcoritamab and odronextamab, in this disease setting.

Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients. 

In this podcast, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Efstathios Kastritis, MD, University of Athens, Athens, Greece, discuss unmet needs in AL amyloidosis, as well as novel immunotherapy strategies being explored. The experts also highlight the prevalence of clonal hematopoiesis of indeterminate potential (CHIP) in this disease setting.

iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, Laurie Sehn, MD, University of British Columbia, Vancouver, Canada, Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, and Sven De Vos, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, discuss novel therapies in NHL, drawing focus on the role of antibody-drug conjugates (ADCs).

MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.

In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.